We have a special investigation piece where we take you inside the black market for cannabis where illegal dispensaries openly break the law, which is all part of a $70 billion nationwide illicit market that’s hurting the legal industry. Melissa Lee has a CNBC investigation report: Weed Killers.

There are more CBD (cannabidiol) products on sale and it’s quickly growing into a billion dollar business. The FDA held its initial hearing on trying to get a better handle on the CBD. Aditi Roy reports.

44 states have now filed a lawsuit accusing pharmaceutical companies of inflating generic drug prices. Meg Tirrell has more with this story.

We speak with Chris Meekins, a research analyst at Raymond James, about the high cost of drugs in the market today. How can folks afford these expensive drugs?

There’s a new drug that’s worth $2M – the biggest price tag ever – and some are saying this gene therapy drug is worth it. Meg Tirrell has more.

Health researchers say there’s little evidence to show that recent progress is a result of the White House’s efforts. They noted that prescriptions have been declining since 2012, before Trump became president.

Outgoing FDA chief Scott Gottlieb releases a much-anticipated draft policy restricting e-cigarette sales to curb an “epidemic” of teen use.

U.S. Surgeon General Jerome M. Adams declared e-cigarette use among kids an “epidemic” in the U.S. on Tuesday, pointing to companies like Juul as problematic.

Two-thirds of Americans want an independent body to oversee prescription drug pricing.

Almost 1 in 5 rural counties in the U.S. saw increases in the number of premature deaths over the past decade — even as most large urban counties saw regular improvements in their premature death rates.

America’s addiction to prescription painkillers is taking a big toll on the workplace. Is enough being done by companies to get it under control?

Over the next couple of weeks two drugs that combat a rare and fatal form of muscular dystrophy will come under review, in what could be a watershed moment for patients.

Insys Therapeutics CEO Michael Babich has stepped down, with company chairman Dr. John Kapoor taking over as CEO. The news comes as the company reported third quarter earnings on Thursday, and shortly after CNBC released an investigative piece on Wednesday on the company, which included allegations of fraud, kickbacks, and aggressive drug marketing behavior by …

Washington’s leading liberal think tank is talking about doing something to control rising drug prices, but will the next president and Congress listen? The Center for American Progress—whose founder John Podesta is now chairing Hillary Clinton’s presidential campaign—on Friday called for a series of steps to address what it called “this growing crisis” of prescription …

Gilead said in its earnings report that it gave insurers steeper-than-expected discounts on its hepatitis C drugs.